Basilea Pharmaceutica has announced the submission of a new drug application (NDA) seeking approval from the US Food and Drug Administration (FDA) for its antibiotic ceftobiprole.

The NDA for ceftobiprole is intended to treat patients with acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and staphylococcus aureus bacteremia (SAB), including right-sided infective endocarditis.

Basilea’s application contains clinical safety and efficacy data from Phase III studies including ERADICATE (SAB), TARGET (ABSSSI) and a study in CABP.

Basilea anticipates an FDA decision on the application during the second quarter of 2024.

Basilea chief medical officer Dr Marc Engelhardt stated: “Staphylococcus aureus bacteremia is a common bloodstream infection with an estimated 120,000 cases in the US per year and is associated with substantial morbidity and mortality.

“Our completed Phase III programme demonstrates the efficacy of ceftobiprole in this complicated infection. The additional successfully completed Phase III studies in ABSSSI and CABP support the broad clinical utility of ceftobiprole.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Basilea has reached licence and distribution agreements for ceftobiprole in more than 80 countries.

The brand is approved and marketed under the names Zevtera and Mabelio in a number of European countries where it treats hospital-acquired bacterial pneumonia (HABP), excluding ventilator-associated bacterial pneumonia (VABP) and CABP.

This content was updated on 25 January 2024